Pfizer study shows benefits of Xtandi for prostate cancer patients

Pfizer and Astellas' cancer therapy Xtandi has demonstrated its potential benefits for the treatment of advanced prostate cancer in a new clinical trial.

Data from the phase III PROSPER trial have shown that Xtandi can deliver significantly improved outcomes among patients with non-metastatic castration-resistant prostate cancer (CRPC).

Patients who received Xtandi plus androgen deprivation therapy (ADT) were able to significantly reduce the risk of developing metastases or death by 71 percent compared to ADT alone. The median for the primary endpoint, metastasis-free survival, was 36.6 months for men who received Xtandi, compared to 14.7 months with ADT alone.

These results will be presented at the 2018 Genitourinary Cancers Symposium in San Francisco, and submitted to the European Medicines Agency and US Food and Drug Administration to support ongoing marketing application processes.

Dr Maha Hussain, of the Robert H Lurie Comprehensive Cancer Center at Northwestern University, said: "In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced prostate cancer."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.